Background And Purpose: The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial.
Methods: ALIAS is a multicenter, blinded, randomized controlled trial. Data on 434 subjects, comprising the ALIAS Part 1 subjects, were analyzed. We examined both the thrombolysis and nonthrombolysis cohorts combined and separately in a "target population" by excluding subjects who would not have been eligible for the ALIAS Part 2 Trial; the latter comprised patients >83 years of age, those with elevated baseline troponin values, and those with in-hospital stroke. We examined the differences in the primary composite outcome, defined as a modified Rankin Scale score of 0 to 1 and/or a National Institutes of Health Stroke Scale score of 0 to 1 at 90 days after randomization.
Results: In the combined thrombolysis plus nonthrombolysis cohorts of the target population, 44.7% of subjects in the ALB group had a favorable outcome compared with 36.0% in the saline group (absolute effect size=8.7%; 95% CI, -2.2% to 19.5%). Among thrombolyzed subjects of the target population, 46.7% had a favorable outcome in the ALB group compared with 36.6% in the saline group (absolute effect size=10.1%; 95% CI, -2.0% to 20.0%).
Conclusions: Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results.
Clinical Trial Registration: URL: http://www.clinicaltrials.gov/ALIAS. Unique identifier: NCT00235495.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118599 | PMC |
| http://dx.doi.org/10.1161/STROKEAHA.110.610980 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Limitation of life-sustaining treatments in Asian ICUs: theory versus practice.
Crit Care
January 2025
Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore.
Conservative management of brain arteriovenous malformations: results of the prospective observation registry of a pragmatic trial.
J Neurosurg
October 2024
4Département de Radiologie, Service de Neuroradiologie Interventionnelle, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec.
Article Synopsis
- The study aimed to track the outcomes of patients with brain arteriovenous malformations (AVMs) who were managed conservatively, revealing key statistics on related morbidity and mortality over a 10-year period.
- Out of 1010 patients initially recruited, 434 were analyzed, with a majority having unruptured low-grade AVMs, demonstrating a 5% occurrence of serious outcomes and a higher risk in those with a history of rupture or older age.
- During the follow-up of approximately 3.2 years, 8% of patients experienced major intracranial hemorrhages, highlighting the ongoing risks associated with conservative management of AVMs.
4 vs 7 points self-monitoring blood glucose in gestational diabetes mellitus on diet modification: randomised clinical trial in a single tertiary centre in Malaysia.
Arch Gynecol Obstet
October 2024
Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz, UKM Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.
Purpose: There is no standardized best method on monitoring of patients with gestational diabetes on diet modification in the country. This study aims to investigate the optimum method of self-monitoring blood glucose.
Methods: This is a randomized clinical trial in a single tertiary centre involving patients with gestational diabetes mellitus (GDM) diagnosed based on NICE guideline on diet modification.
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial.
Lancet Neurol
September 2024
Neuroradiologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Article Synopsis
- - The TENSION trial evaluated the long-term safety and effectiveness of endovascular thrombectomy for patients with ischemic stroke and large infarcts, demonstrating favorable outcomes at 90 days, with a follow-up extending to 12 months.
- - Conducted across various hospitals in Europe and Canada, the trial involved patients aged 18 and older with acute ischemic strokes caused by large vessel occlusions, comparing results between those receiving thrombectomy plus medical care versus medical care alone.
- - Out of 253 enrolled patients, results indicated significant insights into functional outcomes, quality of life, and mental health aspects like anxiety and depression, although the trial concluded early due to promising efficacy in the treatment group.
HEX17(Neumifil): An intranasal respiratory biotherapeutic with broad-acting antiviral activity.
Antiviral Res
August 2024
University of St Andrews, North Haugh, St Andrews, Fife, KY16 9ST, UK. Electronic address:
Broad-acting antiviral strategies to prevent respiratory tract infections are urgently required. Emerging or re-emerging viral diseases caused by new or genetic variants of viruses such as influenza viruses (IFVs), respiratory syncytial viruses (RSVs), human rhinoviruses (HRVs), parainfluenza viruses (PIVs) or coronaviruses (CoVs), pose a severe threat to human health, particularly in the very young or old, or in those with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). Although vaccines remain a key component in controlling and preventing viral infections, they are unable to provide broad-spectrum protection against recurring seasonal infections or newly emerging threats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!